Literature DB >> 11504799

Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.

Y Oda1, E D Kharasch.   

Abstract

Methadone and levo-alpha-acetylmethadol (LAAM) are opioid agonists used for analgesia and preventing opiate withdrawal. Methadone is sequentially N-demethylated to the inactive metabolites 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP). LAAM is essentially a prodrug that undergoes bioactivation via sequential N-demethylation to levo-alpha-acetyl-N-normethadol (nor-LAAM) and levo-alpha-acetyl-N,N-dinormethadol (dinor-LAAM). Methadone and LAAM are metabolized by CYP3A4 in human liver. Since they are administered orally, and CYP3A4 is expressed in human intestine, we tested the hypotheses that human intestine can metabolize methadone and LAAM, and evaluated the participation of CYP3A4. Intestinal microsomal methadone N-demethylation exhibited hyperbolic noncooperative kinetics and biphasic Eadie-Hofstee plots. Using a dual-enzyme Michaelis-Menten model, K(m) values were 11 and 1200 microM for EDDP and 23 and 930 microM for EMDP formation, respectively. CYP3A4 inhibitors (troleandomycin and ketoconazole) inhibited EDDP and EMDP formation by >70%. Methadone N-demethylation by CYP3A4 showed biphasic Eadie-Hofstee plots without evidence of positive cooperativity; K(m) values were 10 and 1100 microM for EDDP and 20 and 1000 microM for EMDP formation. Intestinal microsomal LAAM and nor-LAAM N-demethylation also exhibited hyperbolic kinetics and biphasic Eadie-Hofstee plots. K(m) values were 21 and 980 microM for nor-LAAM from LAAM and 18 and 1200 microM for dinor-LAAM from nor-LAAM. Troleandomycin and ketoconazole inhibited N-demethylation by >70%. LAAM and nor-LAAM metabolism by CYP3A4 showed biphasic Eadie-Hofstee plots without evidence of positive cooperativity; K(m) values were 8 and 1300 microM, 6 and 950 microM, respectively. Predicted in vivo intestinal extraction of methadone and LAAM is 21 and 33%, respectively. We conclude that methadone, LAAM, and nor-LAAM are metabolized by human intestinal microsomes; CYP3A4 is the predominant cytochrome P450 isoform; CYP3A4-catalyzed methadone, LAAM, and nor-LAAM metabolism is characterized by noncooperative, multisite kinetics; and intestinal metabolism may contribute to presystemic methadone inactivation and LAAM bioactivation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504799

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.

Authors:  Mohit P Chopra; Zachary Feldman; Michael J Mancino; Alison Oliveto
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

4.  Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.

Authors:  Taha Ahmad; Samie Sabet; Donald A Primerano; Lauren L Richards-Waugh; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

Review 5.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Relationship between methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) in urine samples from Norwegian prisons.

Authors:  Jean-Paul Bernard; Mimi Stokke Opdal; Ritva Karinen; Jørg Mørland; Hassan Z Khiabani
Journal:  Eur J Clin Pharmacol       Date:  2007-06-19       Impact factor: 2.953

7.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 8.  Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.

Authors:  Taha Ahmad; Monica A Valentovic; Gary O Rankin
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

Review 9.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.